CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 27 enrolled
Drug / intervention
Vaginal estradiol tabletsdrug
Likely dose
Vaginal estradiol tablets 10mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05551949
NCT05551949Phase 4Completed

Mechanisms of Successful Vaginal Estrogen Prophylaxis for Postmenopausal Women With Recurrent Urinary Tract Infections: Urogenital Microbiota and Host Immune Responses

Johns Hopkins University·interventional·Posted Sep 23, 2022·Updated Mar 5, 2026

In Brief

A Phase 4 clinical trial evaluating Vaginal estradiol tablets for Recurrent Urinary Tract Infection and 2 related conditions. Completed, enrolled 27 participants across 1 site.

Detailed Summary

Among postmenopausal women who suffer from recurrent urinary tract infections (UTI), vaginal estrogen therapy prevents UTI recurrences for 50% of sufferers. This research will investigate why some women benefit but others do not, focusing on (a) the effects of vaginal estrogen therapy on the bacteria that inhabit the vagina and bladder, (b) its influence on immune responses in both compartments, and (c) the extent to which those changes are critical to successful UTI prevention. The findings will be a first step in the development of more effective strategies to prevent UTI, one of the most common and costly benign urologic conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
20222023202420252026
First PostedSep 23, 2022
Enrollment StartJan 1, 2022
Primary CompletionJun 30, 2025
Study CompletionAug 31, 2025
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 3.8 years ago

Interventions

Vaginal estradiol tabletsdrug

Vaginal estradiol tablets (10mcg).